Bio Specifics Technologies is the developer of an injectable collagenase, XIAFLEX®, for 12 clinical indications. Currently, XIAFLEX is marketed in the U.S. for the treatment of adult Dupuytren’s contracture patients with a palpable cord by Auxilium Pharmaceuticals, and is also in clinical development for the treatment of several additional indications. BSTC is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in phase 2 clinical trials.  For more information visit the company’s Web site at: www.biospecifics.com

Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital’s management is committed to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is focused on enhancing the goals of clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client. For more information on Aegis Capital, visit www.aegiscapcorp.com.

Let us hear your thoughts below: